Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent

详细信息    查看全文

• 作者：Paul S. Yamauchi ; MD ; PhD^a ; ^b ; ^{paulyamauchi@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Robert Bissonnette ; MD^c ; Henrique D. Teixeira ; PhD ; MBA^d ; Wendell C. Valdecantos ; MD^d
• 关键词：adalimumab ; etanercept ; failure ; infliximab ; psoriasis ; switching ; tumor necrosis factor antagonist
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：75
• 期：3
• 页码：612-618.e6
• 全文大小：491 K

文摘

Tumor necrosis factor (TNF) antagonists have improved outcomes for patients with psoriasis, but some patients are unresponsive to treatment (primary failure) or lose an initially effective response (secondary failure).

Objective

We sought to systematically investigate the efficacy and safety of a second TNF antagonist after failure of a first TNF antagonist.

Methods

Published primary studies evaluating the efficacy of switching TNF antagonists after failure were systematically extracted.

Results

Fifteen studies were included. Although response rates to a second TNF antagonist were lower than for a first, a substantial proportion of patients in every study achieved treatment success. Week-24 response rates for a second antagonist were 30% to 74% for a 75% improvement in Psoriasis Area and Severity Index score and 20% to 70% for achieving a Physician Global Assessment score of 0/1; mean improvements in Dermatology Life Quality Index ranged from −3.5 to −13. In general, patients who experienced secondary failure achieved better responses than patients with primary failure. Adverse event incidences ranged from 20% to 71%, without unexpected adverse events; 0% to 11% of patients experienced serious adverse events.

Limitations

There was no common definition of treatment failure across these studies of varied design.

Conclusions

Some patients benefit from switching to a second TNF antagonist after failure of a first TNF antagonist, with improved quality of life.